Editor's Picks

Open Access Perspective
Future perspectives: targeting fibroblast growth factor receptor 1 to enhance the efficacy of immunotherapy
Fibroblast growth factor receptor 1 (FGFR1) plays a critical role in the progression of various cancers through its involvement in cell proliferation, survival, and differentiation. More recently, FGFR1 has been implicated in the mechanisms of immune evasion, particularly its role in resistance to immune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab. Targeting FGFR1 with monoclonal antibodies and tyrosine kinase inhibitors has emerged as a promising therapeutic strategy to enhance ICI efficacy by altering the tumor microenvironment and countering immune suppression. Preclinical studies demonstrate that combining FGFR1 inhibitors, such as the novel monoclonal antibody OM-RCA-01, with ICIs significantly improves antitumor activity, enhancing T cell responses and cytokine production. This article explores the role of FGFR1 in cancer biology, its contribution to immunotherapy resistance, and the therapeutic potential of targeting FGFR1 to enhance the efficacy of ICIs.
Open Access Review
Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation
Neoantigen-based immunotherapy has emerged as a transformative approach in cancer treatment, offering precision medicine strategies that target tumor-specific antigens derived from genetic, transcriptomic, and proteomic alterations unique to cancer cells. These neoantigens serve as highly specific targets for personalized therapies, promising more effective and tailored treatments. The aim of this article is to explore the advances in neoantigen-based therapies, highlighting successful treatments such as vaccines, tumor-infiltrating lymphocyte (TIL) therapy, T-cell receptor-engineered T cells therapy (TCR-T), and chimeric antigen receptor T cells therapy (CAR-T), particularly in cancer types like glioblastoma (GBM). Advances in technologies such as next-generation sequencing, RNA-based platforms, and CRISPR gene editing have accelerated the identification and validation of neoantigens, moving them closer to clinical application. Despite promising results, challenges such as tumor heterogeneity, immune evasion, and resistance mechanisms persist. The integration of AI-driven tools and multi-omic data has refined neoantigen discovery, while combination therapies are being developed to address issues like immune suppression and scalability. Additionally, the article discusses the ongoing development of personalized immunotherapies targeting tumor mutations, emphasizing the need for continued collaboration between computational and experimental approaches. Ultimately, the integration of cutting-edge technologies in neoantigen research holds the potential to revolutionize cancer care, offering hope for more effective and targeted treatments.
Open Access Review
Modulation of anti-tumour immunity by XPO1 inhibitors
Exportin-1 (XPO1) is a nuclear export protein that, when overexpressed, can facilitate cancer cell proliferation and survival and is frequently overexpressed or mutated in cancer patients. As such, selective inhibitors of XPO1 (XPO1i) function have been developed to inhibit cancer cell proliferation and induce apoptosis. This review outlines the evidence for the immunomodulatory properties of XPO1 inhibition and discusses the potential for combining and sequencing XPO1i with immunotherapy to improve the treatment of patients with cancer. Selinexor is a first-in-class XPO1i that is FDA-approved for the treatment of patients with relapsed and refractory (RR) multiple myeloma and RR diffuse large B cell lymphoma. In addition to the cancer cell intrinsic pro-apoptotic activity, increasing evidence suggests that XPO1 inhibition has immunomodulatory properties. In this review, we describe how XPO1i can lead to a skewing of macrophage polarisation, inhibition of neutrophil extracellular traps, modulation of immune checkpoint expression, blockade of myeloid-derived suppressor cells (MDSCs) and sensitisation of cancer cells to T cell and NK (natural killer) cell immunosurveillance. As such, there is an opportunity for selinexor to enhance immunotherapy efficacy and thus a need for clinical trials assessing selinexor in combination with immunotherapies such as immune checkpoint inhibitors, direct targeting monoclonal antibodies, chimeric antigen receptor (CAR)-T cells and cereblon E3 ligase modulators (CELMoDs).

Articles

Latest
Most Viewed
Most Downloaded
Most Cited
Open Access Review
Dysbiosis and colorectal cancer: conducive factors, biological and molecular role, and therapeutic prospectives
Gurkaranjot Singh ... Vikrant Rai
Published: June 27, 2025 Explor Target Antitumor Ther. 2025;6:1002329
196 7 0
Open Access Review
Biliary tract cancers: advances in diagnostic and management
James Gutmans, Hiba Mechahougui
Published: June 23, 2025 Explor Target Antitumor Ther. 2025;6:1002328
230 13 0
Open Access Perspective
Future perspectives: targeting fibroblast growth factor receptor 1 to enhance the efficacy of immunotherapy
Ilya Tsimafeyeu
Published: June 20, 2025 Explor Target Antitumor Ther. 2025;6:1002327
1263 24 0
Open Access Review
An overview of the feasibility of nanomedicine in pancreatic cancer theranostics
Kyriakos Kokkinogoulis ... Mersini Makropoulou
Published: June 18, 2025 Explor Target Antitumor Ther. 2025;6:1002326
337 9 0
Open Access Original Article
Comparison of outcomes of neoadjuvant chemotherapy in BRCA1- versus BRCA2-associated breast and ovarian cancers
Anna Sokolenko ... Evgeny Imyanitov
Published: June 18, 2025 Explor Target Antitumor Ther. 2025;6:1002325
249 6 0
Open Access Review
Osteosarcoma: current insights and advances
Guraustin S. Brar ... Yujiang Fang
Published: June 15, 2025 Explor Target Antitumor Ther. 2025;6:1002324
358 16 0
Open Access Review
Current strategies for the design of PROTAC linkers: a critical review
Robert I. Troup ... Matthias G. J. Baud
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
35765 3443 251
Open Access Review
The impact of tumour pH on cancer progression: strategies for clinical intervention
Carol Ward ... Simon P Langdon
Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
23246 784 105
Open Access Review
Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response
Pierluigi De Santis ... Palma Fedele
Published: February 28, 2024 Explor Target Antitumor Ther. 2024;5:232–250
This article belongs to the special issue Innovative Strategies to Target Triple-negative Breast Cancer
10868 215 1
Open Access Review
Novel approaches for the rational design of PROTAC linkers
Almaz Zagidullin ... Emil Bulatov
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
9695 519 40
Open Access Review
Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer
Sarah J Taylor ... Simon P Langdon
Published: February 29, 2020 Explor Target Antitumor Ther. 2020;1:26–52
9645 209 3
Open Access Review
Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
Rachael Arthur ... Graham Packham
Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131–152
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
9200 305 18
Open Access Review
Current strategies for the design of PROTAC linkers: a critical review
Robert I. Troup ... Matthias G. J. Baud
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
35765 3443 251
Open Access Perspective
Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma
Sayuri Yoshikawa ... Satoru Matsuda
Published: December 27, 2022 Explor Target Antitumor Ther. 2022;3:817–827
This article belongs to the special issue Theranostic Frontiers in Neuro-Oncology
5166 1746 8
Open Access Perspective
Potential tactics with vitamin D and certain phytochemicals for enhancing the effectiveness of immune-checkpoint blockade therapies
Ai Tsuji ... Satoru Matsuda
Published: June 30, 2023 Explor Target Antitumor Ther. 2023;4:460–473
This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
4055 1227 3
Open Access Perspective
Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma
Sayuri Yoshikawa ... Satoru Matsuda
Published: August 24, 2023 Explor Target Antitumor Ther. 2023;4:556–568
This article belongs to the special issue Cancer Immunotherapy and Tumor Microenvironment
3918 1127 1
Open Access Review
The impact of tumour pH on cancer progression: strategies for clinical intervention
Carol Ward ... Simon P Langdon
Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
23246 784 105
Open Access Review
Novel approaches for the rational design of PROTAC linkers
Almaz Zagidullin ... Emil Bulatov
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
9695 519 40
Open Access Review
Current strategies for the design of PROTAC linkers: a critical review
Robert I. Troup ... Matthias G. J. Baud
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:273–312
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
35765 3443 251
Open Access Review
The impact of tumour pH on cancer progression: strategies for clinical intervention
Carol Ward ... Simon P Langdon
Published: April 28, 2020 Explor Target Antitumor Ther. 2020;1:71–100
23246 784 105
Open Access Review
Novel approaches for the rational design of PROTAC linkers
Almaz Zagidullin ... Emil Bulatov
Published: October 30, 2020 Explor Target Antitumor Ther. 2020;1:381–390
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
9695 519 40
Open Access Review
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
Vincenza Caputo ... Stefania Napolitano
Published: February 28, 2023 Explor Target Antitumor Ther 2023;4:102–138
6203 141 39
Open Access Review
The clinical advances of proteolysis targeting chimeras in oncology
Hao Xie ... Jason B. Fleming
Published: December 31, 2021 Explor Target Antitumor Ther. 2021;2:511–521
This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
6652 238 25
Open Access Review
Potential role of resveratrol and its nano-formulation as anti-cancer agent
Akshay Kumar ... Dilpreet Singh
Published: October 31, 2022 Explor Target Antitumor Ther. 2022;3:643–658
This article belongs to the special issue Plant Extracts as an Infinite Resource for New Anticancer Agents
4162 61 24

Special Issues

Ongoing Special lssues
Completed Special lssues
Artificial Intelligence Technology in Tumor Radiotherapy
Guest Editor: Prof. Tuan D. Pham
Submission Deadline: September 30, 2025
Published Articles: 0
​Liquid Biopsy: Has Already Changed the Clinical Decision-Making in Solid Tumors Treatment?​​
Guest Editor: Dr. Giulia Martini
Submission Deadline: June 30, 2025
Published Articles: 3
Predictive and Prognostic Biomarkers in Cancer: Towards the Precision Medicine Era
Guest Editors: Prof. Luca Falzone; Dr. Antonio Rizzo; Dr. Stefano Marletta; Dr. Graziana Spoto
Submission Deadline: February 28, 2025
Published Articles: 3
Potential Clinical Applications of Inorganic Nanomaterials in Cancer
Guest Editor: Prof. Javier Reguera
Submission Deadline: June 30, 2025
Published Articles: 1
Potential of Non-Coding RNAs in Cancer Research and Treatment
Guest Editors: Prof. Francesco Bertoni; Dr. Luciano Cascione
Submission Deadline: June 30, 2025
Published Articles: 1
Novel Biomarkers in the Immunotherapy Era
Guest Editors: Dr. Carminia Maria Della Corte; Dr. Floriana Morgillo; Dr. Caterina De Rosa
Submission Deadline: June 30, 2025
Published Articles: 2
Comprehensive Immunotherapy of Solid Tumors
Guest Editor: Dr. Michela Valeria Rita Starace
Submission Deadline: October 31, 2024
Published Articles: 4
Advances in Cancer Genomics and Therapeutic Targets
Guest Editor: Prof. Apostolos Zaravinos
Submission Deadline: June 30, 2025
Published Articles: 2
Molecular Mechanisms and Intervention Options in Metastatic Spread of Cancer
Guest Editor: Dr. Katrin Sak
Submission Deadline: June 30, 2025
Published Articles: 2
Use of Different Radiation Treatment Modalities in Cancer Therapy: The Role of Inflammation and Immune Response
Guest Editor: Prof. Alexandros Georgakilas
Submission Deadline: May 31, 2025
Published Articles: 2
Mechanisms of Targeted Therapy Resistance and Reversal Strategies
Guest Editor: Prof. Pier Paolo Piccaluga
Submission Deadline: December 31, 2024
Published Articles: 3
Cancer Epigenetics: Implications for Novel Therapeutic Strategies
Guest Editor: Prof. Mingzhou Guo
Submission Deadline: February 01, 2025
Published Articles: 2
Posttranslational Modifications in Health and Disease
Guest Editor: Prof. Oliver Krämer
Submission Deadline: December 31, 2024
Published Articles: 4
The Role of Bcl-2 Family Proteins in Cancer Progression and Their Relevance to Cancer Therapy
Guest Editors: Dr. Donatella Del Bufalo; Dr. Germain Gillet
Submission Deadline: November 30, 2021
Published Articles: 5

Focus

Overview of DNA Damage Laboratory and Group
Prof. Alexandros Georgakilas
May. 18, 2023 2769

Membership

Journal Indexing
Journal Metrics
Speed 2025

From Submission to First Decision: 6 days

From First decision to Acceptance: 91 days

From Acceptance to Publication: 23 days

Article Usage (total)

Views: 1,011,530

Downloads: 26,363

Acceptance Rate

28%; 2024

49%; 2023

42%; 2022

Follow the Journal